News

IGEM Therapeutics awarded “Best Start-up Biotech Company” at the 2018 OBN Awards

London, 12 October 2018 – IGEM Therapeutics (IGEM), an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, today announced...

Read more

IGEM Therapeutics shortlisted as a finalist in the “Best Start-up Biotech Company”

IGEM Therapeutics shortlisted as a finalist in the “Best Start-up Biotech Company” category of the 2018 OBN Awards  London, 22 August 2018– IGEM Therapeutics (IGEM)...

Read more

IGEM Therapeutics announces UK government funding to develop a novel IgE antibody targeting solid tumours

£1.45 million grant from Innovate UK Biomedical Catalyst Funds enable IGEM to progress second product candidate towards the clinic London, 9 May 2018 – IGEM...

Read more

IONTAS and IGEM Therapeutics collaborate to identify novel IgE antibodies for cancer targets

Cambridge, UK, 04 April 2018: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, announced today that it will collaborate...

Read more

£2 million raised from Epidarex Capital

Raises £2 million from Epidarex Capital to progress pipeline of IgE antibody drug candidates to treat cancer

Read more